Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of an additional 28 weeks of treatment
with pegsunercept for subjects who have completed treatment in a previous double-blind study
(20000201 or 20000198). In addition, this study will evaluate the efficacy and the
feasibility of subject self-administration on an outpatient basis.